Cargando…

Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma

BACKGROUND: Immune checkpoint inhibitors have improved survival in advanced stage melanoma patients. Rates of new primary melanomas (NPM) in patients with prior melanoma have been reported to be as high as 12%. Little is currently known regarding the frequency or characteristics of NPMs occurring in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pennington, Thomas E, Zhao, Cathy Yunjia, Colebatch, Andrew J, Fernandez‐Peñas, Pablo, Guitera, Pascale, Burke, Hazel, Scolyer, Richard A, Menzies, Alexander M, Carlino, Matteo S, Lo, Serigne, Long, Georgina V, Saw, Robyn PM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9303670/ https://www.ncbi.nlm.nih.gov/pubmed/35188271 http://dx.doi.org/10.1111/ajd.13807

Ejemplares similares

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas
por: Gaetano, Licata, et al.
Publicado: (2022)

Clinicopathological Characteristics Predicting Further Recurrence and Survival Following Resection of In-Transit Melanoma Metastases
por: Lawless, Anna K., et al.
Publicado: (2022)

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
por: Shklovskaya, Elena, et al.
Publicado: (2020)

Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients
por: Gide, Tuba N., et al.
Publicado: (2019)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0–II) melanoma
por: Thompson, Jake R, et al.
Publicado: (2022)

Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites
por: Conway, Jordan W, et al.
Publicado: (2022)

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2020)

Dermoscopic features and screening strategies for the detection of small‐diameter melanomas
por: Regio Pereira, Amanda, et al.
Publicado: (2022)

Advances in the use of reflectance confocal microscopy in melanoma
por: Waddell, Andréanne, et al.
Publicado: (2018)

Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy
por: Attrill, Grace Heloise, et al.
Publicado: (2022)

OTHR-08. PREDICTION OF RISK OF CENTRAL NERVOUS SYSTEM METASTASIS FOR AJCC 8(TH) EDITION STAGE III MELANOMA PATIENTS
por: Haydu, Lauren, et al.
Publicado: (2019)

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies
por: Adegoke, Nurudeen A, et al.
Publicado: (2023)

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach
por: Mao, Yizhe, et al.
Publicado: (2023)

Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients
por: Pirozyan, Mehdi R., et al.
Publicado: (2020)

Junctional Nevus and Early Melanoma on Sun-Damaged Skin of the Head/Neck: a Clinico-Pathologic Challenge
por: Moscarella, Elvira, et al.
Publicado: (2023)

Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas
por: Quek, Camelia, et al.
Publicado: (2019)

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma
por: Diefenbach, Russell J., et al.
Publicado: (2019)

Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab
por: Nahar, Kazi J, et al.
Publicado: (2020)

Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial)
por: Yan, Mabel K., et al.
Publicado: (2023)

Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets
por: Gide, Tuba N., et al.
Publicado: (2021)

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
por: Lee, Jenny H., et al.
Publicado: (2020)

Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy
por: Shiuan, Eileen, et al.
Publicado: (2017)

Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes
por: Newell, Felicity, et al.
Publicado: (2022)

Improving Selection for Sentinel Lymph Node Biopsy Among Patients With Melanoma
por: Miller, James R., et al.
Publicado: (2023)

Use of shared care and routine tests in follow-up after treatment for localised cutaneous melanoma
por: Lim, Wei-Yin, et al.
Publicado: (2018)

The Impact of Surveillance Imaging Frequency on the Detection of Distant Disease for Patients with Resected Stage III Melanoma
por: Dieng, Mbathio, et al.
Publicado: (2022)

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
por: Wilmott, James S., et al.
Publicado: (2012)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
por: Lim, Su Yin, et al.
Publicado: (2017)

Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition
por: Park, John J., et al.
Publicado: (2021)

Dabrafenib and its potential for the treatment of metastatic melanoma
por: Menzies, Alexander M, et al.
Publicado: (2012)

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
por: Lee, J H, et al.
Publicado: (2019)

Perspectives and Experiences of Patient-Led Melanoma Surveillance Using Digital Technologies From Clinicians Involved in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study
por: Drabarek, Dorothy, et al.
Publicado: (2022)

High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
por: Quek, Camelia, et al.
Publicado: (2021)

PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma
por: Parakh, Sagun, et al.
Publicado: (2021)

Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting
por: Seviiri, Mathias, et al.
Publicado: (2022)

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
por: Parakh, Sagun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g9j02dog9s6kb7idps8vvoic4k